Literature DB >> 27171648

Diagnoses of Hidradenitis Suppurativa in the United States, 1979-2012.

Kathleen McMillan1.   

Abstract

Hidradenitis suppurativa (HS) is rarely diagnosed in the United States. Delayed diagnosis is a significant problem in the management of HS. In the past decade, there has been an increase in HS research. To determine whether those efforts have led to an increase in diagnoses, an analysis of visits to physicians in the United States from 1979 to 2012 was performed, using National Center for Health Statistics (NCHS) databases. Patient visits to private physician offices, hospital outpatient departments, and emergency rooms were analyzed. An increase in visit rates at outpatient departments from 2003-2007 [6.3/100,000, 95% confidence interval (CI) 2.9-9.8] to 2008-2010 (30.4/100,000, 95% CI 13.9-46.9; p = 0.017) was found. Converting the data to estimated numbers of patients, a 7-fold increase in patients from 2002-2007 (2.5/100,000, 95% CI 1.4-3.6) to 2008-2010 (16.9/100,000, 95% CI 7.8-26.1; p = 0.003) was found. No significant increase in patient or patient visit rates were found when analyzing visits in the physician office setting or combined office and hospital settings. Localization of increased diagnosis to outpatient departments may reflect the recent increase in clinical research. NCHS data can be useful in monitoring rates of HS diagnosis as an outcome of increased awareness of the disease.

Entities:  

Keywords:  Database analysis; Epidemiology; Hidradenitis suppurativa; Survey; Temporal trends

Year:  2015        PMID: 27171648      PMCID: PMC4857847          DOI: 10.1159/000439438

Source DB:  PubMed          Journal:  Skin Appendage Disord        ISSN: 2296-9160


  19 in total

1.  An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa.

Authors:  E J Giamarellos-Bourboulis; E Pelekanou; A Antonopoulou; H Petropoulou; F Baziaka; V Karagianni; N Stavrianeas; H Giamarellou
Journal:  Br J Dermatol       Date:  2007-12-11       Impact factor: 9.302

2.  Hidradenitis suppurativa markedly decreases quality of life and professional activity.

Authors:  Łukasz Matusiak; Andrzej Bieniek; Jacek C Szepietowski
Journal:  J Am Acad Dermatol       Date:  2010-04       Impact factor: 11.527

3.  Diagnostic delay in hidradenitis suppurativa is a global problem.

Authors:  D M Saunte; J Boer; A Stratigos; J C Szepietowski; I Hamzavi; K H Kim; K Zarchi; C Antoniou; L Matusiak; H W Lim; M Williams; H H Kwon; M A Gürer; F Mammadova; A Kaminsky; E Prens; H H van der Zee; V Bettoli; S Zauli; J Hafner; S Lauchli; L E French; H Riad; M El-Domyati; H Abdel-Wahab; B Kirby; G Kelly; P Calderon; V del Marmol; F Benhadou; J Revuz; C C Zouboulis; I Karagiannidis; K Sartorius; L Hagströmer; E McMeniman; N Ong; M Dolenc-Voljc; Z B Mokos; L Borradori; R E Hunger; C Sladden; N Scheinfeld; N Moftah; L Emtestam; J Lapins; N Doss; I Kurokawa; G B E Jemec
Journal:  Br J Dermatol       Date:  2015-11-03       Impact factor: 9.302

4.  Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota.

Authors:  Benjamin G Vazquez; Ali Alikhan; Amy L Weaver; David A Wetter; Mark D Davis
Journal:  J Invest Dermatol       Date:  2012-08-30       Impact factor: 8.551

5.  A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.

Authors:  Masahiro Amano; Annika Grant; Francisco A Kerdel
Journal:  Int J Dermatol       Date:  2010-08       Impact factor: 2.736

Review 6.  Hidradenitis suppurativa.

Authors:  F William Danby; Lynette J Margesson
Journal:  Dermatol Clin       Date:  2010-10       Impact factor: 3.478

7.  Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.

Authors:  Alexa B Kimball; Francisco Kerdel; David Adams; Ulrich Mrowietz; Joel M Gelfand; Robert Gniadecki; Errol P Prens; Joel Schlessinger; Christos C Zouboulis; Hessel H van der Zee; Marie Rosenfeld; Parvez Mulani; Yihua Gu; Susan Paulson; Martin Okun; Gregor B E Jemec
Journal:  Ann Intern Med       Date:  2012-12-18       Impact factor: 25.391

8.  A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa.

Authors:  Robert A Lee; Erica Dommasch; James Treat; Joslyn Sciacca-Kirby; Samuel Chachkin; Jennifer Williams; Daniel B Shin; James J Leyden; Carmela Vittorio; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2009-01-31       Impact factor: 11.527

9.  Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report.

Authors:  H H van der Zee; E P Prens
Journal:  Dermatology       Date:  2013-05-25       Impact factor: 5.366

10.  Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States.

Authors:  Irene Cosmatos; Amy Matcho; Rachel Weinstein; Michael O Montgomery; Paul Stang
Journal:  J Am Acad Dermatol       Date:  2012-08-24       Impact factor: 11.527

View more
  2 in total

1.  Hidradenitis Suppurativa in the United States: Insights From the National Inpatient Sample (2008-2017) on Contemporary Trends in Demographics, Hospitalization Rates, Chronic Comorbid Conditions, and Mortality.

Authors:  Amie Patel; Anjali Patel; Dhanshree Solanki; Uvesh Mansuri; Aanandita Singh; Purnima Sharma; Shantanu Solanki
Journal:  Cureus       Date:  2022-05-05

2.  Descriptive Epidemiology of Hidradenitis Suppurativa in Greece: A Study of 152 Cases.

Authors:  Alexandros C Katoulis; Aikaterini I Liakou; Nikolaos Rotsiamis; Stefanos Bonovas; Evangelia Bozi; Efstathios Rallis; Christos Christodoulou; Dimitrios Rigopoulos
Journal:  Skin Appendage Disord       Date:  2017-05-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.